The therapeutic potential of CB1R blockade for obesity and its complications has prompted a keen interest among researchers to design and develop compounds that act on peripheral CB1Rs, maintaining the beneficial cardiometabolic and anti-obesity effects and avoiding central-nervous-system-mediated adverse reactions. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.